AIM and small-cap hub
Get the lowdown on smaller company shares and all that matters on the junior market.
The performance of new AIM listings – if investors can access them
In the past three years, new AIM admissions have had a 12% first-day premium.
by Andrew Hore
Why Novacyt is back in favour and AIM’s other big movers
Investors react as the Covid testing firm continues to adapt to life after a vaccine.
by Graeme Evans
Stockopedia: how to find companies with the strongest ‘moats’
Warren Buffett’s idea of spotting firms with a durable competitive edge still holds water.
by Ben Hobson
Richard Beddard: scoring a music stock with Beatles connections
Being For The Benefit of Focusrite - plus a reader question on Dewhurst.
by Richard Beddard
Stockwatch: a good IT share for patient buyers
Redcentric is at a watershed moment, but could be about to prosper.
by Edmond Jackson